BofA sees Apogee with ‘best-in-class drug’ potential, starts with a Buy

As previously reported, BofA analyst Geoff Meacham initiated coverage of Apogee Therapeutics with a Buy rating and $80 price target. The clinical-stage biotechnology company is developing long-acting biologics for the treatment of atopic dermatitis, or AD, asthma, and chronic obstructive pulmonary disease, or COPD, which the firm highlights as “three of the largest and most dynamic I&I markets globally.” The firm anticipates substantial growth for this segment of the market in the next decade and tells investors Apogee is “on the path to produce best-in-class drugs from a dosing frequency and efficacy perspective.”